{"id":"W2701201582","doi":"10.1358/dot.2017.53.5.2613690","title":"Brodalumab: The first anti-IL-17 receptor agent for psoriasis","year":2017,"lang":"en","type":"review","venue":"Drugs of today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Secukinumab; Ixekizumab; Psoriasis Area and Severity Index; Psoriasis; Ustekinumab; Psoriatic arthritis; Dermatology; Interleukin 17; Clinical trial; Erythroderma; Immunology; Internal medicine; Adalimumab; Immune system; Disease","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004090101,0.0007321572,0.0006068725,0.0005216069,0.0003478382,0.0009108399,0.0005808054,0.001042925,0.007306969],"category_scores_gemma":[0.0004645211,0.0002069532,0.0005892211,0.0002152704,0.0002144434,0.0004429994,0.0004533847,0.002635266,0.006258456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000566823,"about_ca_system_score_gemma":0.0006205406,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008537576,"about_ca_topic_score_gemma":0.002040497,"domain_scores_codex":[0.9997573,0.00003410981,0.00001459398,0.00003799328,0.00008807617,0.00006798818],"domain_scores_gemma":[0.9998096,0.00001940296,0.00002419087,0.00000946201,0.00005497455,0.00008248448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002542682,0.0008323741,0.0009901704,0.001588547,0.0001865105,0.001255794,0.00008180101,0.0002893801,0.03486802,0.001664104,0.1474055,0.8082951],"study_design_scores_gemma":[0.002736715,0.003231919,0.003743277,0.0004611696,0.0001475347,0.003641265,0.00001551073,0.0003724772,0.01493353,0.0003226872,0.9703532,0.00004068579],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.09354915,0.7029866,0.01113346,0.01685652,0.0169618,0.002022784,0.006319543,0.004006501,0.1461636],"genre_scores_gemma":[0.4121186,0.3253724,0.02139258,0.03833162,0.005531207,0.001576383,0.01164087,0.0005460313,0.1834902],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007306969,"threshold_uncertainty_score":0.02444422,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06135471088143997,"score_gpt":0.3181274239703031,"score_spread":0.2567727130888632,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}